Program
arlocabtagene autoleucel
Also written as “BMS-986393”, “Arlocabtagene Autoleucel” and “CC-95266”.
Its studies are mostly in Multiple Myeloma, led by Bristol-Myers Squibb.
Furthest: phase 3, since Sep 24, 20243 company-led studies, 2 open or runningNext primary completion: Dec 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 32 open or running | phase 3since Sep 24, 2024 | Dec 14, 2020 | Dec 30, 2027phase 3 · NCT06615479 |
- Named in Bristol-Myers Squibb’s own pipeline as
arlo-cel
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 14, 2020First study: phase 1 study in Multiple MyelomaFirst studyNCT04674813 · 130 enrolled · United States
- Feb 28, 2024Phase 2 study in Multiple MyelomaNCT06297226 · 230 planned · United States, Australia, Canada and more
- Sep 24, 2024Phase 3 study in RecurrenceNCT06615479 · 440 planned · United States, Argentina, Australia and more
Ahead
- Dec 30, 2027Primary completion: phase 3 study in RecurrenceNCT06615479
TargetBeta
“A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human G-protein coupled receptor family C group 5 member D (GPRC5D), with potential immunostimulating and antineoplastic activities. Upon leukapheresis…”NCIt, read by Claude
Other programs on GPRC5D
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ramantamig | Johnson & Johnson | phase 3 | 8 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| QLS4131rule | Qilu Pharmaceutical | phase 3 | 3 |
| QLS32015rule | Qilu Pharmaceutical | phase 3 | 2 |
| vemzatatug vedotin | AstraZeneca | phase 2 | 1 |
| MBS314 for Injectionrule | beijing-mabworks-biotech-co-ltd | phase 2 | 1 |
| REGN17372rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| Anti-GPRC5D Monoclonal Antibody SAR446523 | Sanofi | phase 1 | 1 |
| tunlucabtagene autoleucel | Bristol-Myers Squibb | phase 1 | 1 |
| TQB2029 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06615479Recurrence · United States, Argentina, Australia and more | 3 | Recruiting | Dec 30, 2027 | 440 |
| NCT06297226Multiple Myeloma · United States, Australia, Canada and more | 2 | Recruiting | Jul 31, 2026 | 230 |
| NCT04674813Multiple Myeloma · United States | 1 | Completed | Dec 22, 2025 | 130 |
How it is read
Names in the registry
- “BMS-986393”, 1 entry
- “Arlocabtagene Autoleucel”, 1 entry
- “CC-95266”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.